My wife works with dialysis patients , she did CKD research at Yale.
Her Renal Dept has been recruiting for PRTO's PATENCY 1 and PATENCY 2 trials .
These trials are double blinded, folks ...no insider info here .
Anyway Dew I'll give you what I have and would appreciate your comments .
Novartis originally had an option on their program ( to improve / maintain patency ( blood flow ) in fistulas , essential for dialysis )
They declined to exercise their option $550m ...or at least they couldn't come to terms .
PRTO IPO'd at $10 a share in 2014 and went ahead on their own ...almost sound like the ZSPH story ( hyperkalemia )
Phase 3 PATENCY 1 was enrolled ahead of schedule and should read out in Dec 2016
Phase 3 PATENCY 2 seemed to have a slowed / delayed enrollment ...may be related to slight change/emphasis in end points ...see clinicaltrials.gov history of changes but is up and running now.
PRTO has funds thru 2017 ...enough to finish PATENCY 1 , but not enough to finish PATENCY 2 . Believe their program is Fast Tracked and also Orphan Drug designated..
PRTO presented at a recent conference ...Webcast is available thru their web site
They also filed a CT order ... SEC confidential treatment order..so I'm wondering if they are back in talks with Novartis ...who you may know has a presence in Renal.
Believe its now Abingworth LLP's 2nd largest position .
Baker Bros and Alta Partners also have positions .
So about Fistula's ( AVF ) and dialysis .
Fistula blockage is a major problem for dialysis patients . My wife deals with it every week. Some of her patients have fistula tracks completely up both arms ...as one fails they start a new one higher up.
Hospitals spend around $17,000 per dialysis patient maintaining or reworking fistula's...PRTO's figures.
So there is a real demand for anything that will reduce Fistula failure.
PRTO thinks they can reduce Fistual failure by 20-30 % with their Vonapantise drug ( applied during creation of the Fistula )
Would appreciate your comments
PRTO has spiked recently ( post conference and CT order )
Thx
Kiwi
PS for anyone else reading this . If their P 3 trial fails , this stock is going to a $1. Risk only what you can afford to lose.
Recent ESPR News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:12:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:11:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:02:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 07:28:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 07:20:06 PM
- Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/05/2024 12:00:00 PM
- Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 08/26/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:03:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2024 07:50:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/12/2024 08:33:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:08:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 11:21:11 AM
- Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/12/2024 10:00:00 AM
- U.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices Climb • IH Market News • 08/12/2024 09:47:41 AM
- Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/07/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:34:24 PM
- Esperion to Report Second Quarter 2024 Financial Results on August 12 • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Esperion to Participate in Upcoming BTIG Biotech Conference • GlobeNewswire Inc. • 07/24/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 12:30:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2024 12:29:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 07:22:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/17/2024 07:11:07 PM
- New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries • GlobeNewswire Inc. • 07/16/2024 12:00:00 PM
- Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM